Skip to main content
SpringerLink
Log in

Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?

  • Letter to the editor
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kari JA, Alhasan KA, Albanna AS, Safdar OY, Shalaby MA, Böckenhauer D. El-Desoky SM Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020. https://doi.org/10.1007/s00467-020-04570-y.

    Article  PubMed  Google Scholar 

  2. Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2016;31:589–94.

    Article  PubMed  Google Scholar 

  3. Mizutani A, Fujinaga S, Sakuraya K, Hirano D, Shimizu T. Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome. Clin Exp Nephrol. 2019;23:244–50.

    Article  CAS  PubMed  Google Scholar 

  4. Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol. 2017;21:671–6.

    Article  CAS  PubMed  Google Scholar 

  5. Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol. 2016;85:340–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

SF has received clinical research funding B at Saitama Children’s Medical Center.

Author information

Authors and Affiliations

  1. Division of Nephrology, Saitama Children’s Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama-city, Saitama, 330-8777, Japan

    Shuichiro Fujinaga & Akira Mizutani

Authors
  1. Shuichiro Fujinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Mizutani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuichiro Fujinaga.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Research Committee and/or National Research Committee at which the study was conducted (approval number 2018-02-19) with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all participants included in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fujinaga, S., Mizutani, A. Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?. Clin Exp Nephrol 24, 1187–1188 (2020). https://doi.org/10.1007/s10157-020-01938-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-020-01938-0

Search

Navigation